Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Repligen Corp (RGEN)

Repligen Corp (RGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,919,801
  • Shares Outstanding, K 56,149
  • Annual Sales, $ 634,440 K
  • Annual Income, $ -25,510 K
  • EBIT $ -27 M
  • EBITDA $ 58 M
  • 60-Month Beta 1.21
  • Price/Sales 11.31
  • Price/Cash Flow 41.15
  • Price/Book 3.62

Options Overview Details

View History
  • Implied Volatility 50.03% ( -1.88%)
  • Historical Volatility 73.57%
  • IV Percentile 43%
  • IV Rank 33.40%
  • IV High 84.92% on 04/07/25
  • IV Low 32.53% on 05/17/24
  • Put/Call Vol Ratio 2.27
  • Today's Volume 36
  • Volume Avg (30-Day) 457
  • Put/Call OI Ratio 3.81
  • Today's Open Interest 11,317
  • Open Int (30-Day) 9,865

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.40
  • Number of Estimates 6
  • High Estimate 0.41
  • Low Estimate 0.38
  • Prior Year 0.33
  • Growth Rate Est. (year over year) +21.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
110.97 +11.06%
on 04/10/25
148.94 -17.26%
on 04/23/25
-0.61 (-0.49%)
since 04/09/25
3-Month
102.96 +19.70%
on 04/07/25
169.00 -27.08%
on 02/20/25
-32.81 (-21.03%)
since 02/07/25
52-Week
102.96 +19.70%
on 04/07/25
182.52 -32.48%
on 01/28/25
-41.65 (-25.26%)
since 05/09/24

Most Recent Stories

More News
1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar

1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar

LUCK : 8.77 (+5.54%)
NOW : 980.06 (+0.57%)
RGEN : 123.24 (-3.61%)
Repligen Corporation to Present at Upcoming May Investor Conferences

RGEN : 123.24 (-3.61%)
RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty

RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty

RGEN : 123.24 (-3.61%)
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y

Repligen Corporation RGEN reported first-quarter 2025 adjusted earnings per share of 39 cents, which beat the Zacks Consensus Estimate of 35 cents. The company had recorded adjusted earnings of 30 cents...

BEAM : 17.41 (+0.93%)
IMCR : 28.40 (-4.67%)
RGEN : 123.24 (-3.61%)
ADMA : 19.98 (-5.75%)
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

RGEN : 123.24 (-3.61%)
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

RGEN : 123.24 (-3.61%)
Repligen: Q1 Earnings Snapshot

Repligen: Q1 Earnings Snapshot

RGEN : 123.24 (-3.61%)
Repligen Reports First Quarter 2025 Financial Results

RGEN : 123.24 (-3.61%)
Repligen (RGEN) Q1 Earnings: What To Expect

Repligen (RGEN) Q1 Earnings: What To Expect

MEDP : 296.03 (-1.59%)
RGEN : 123.24 (-3.61%)
WST : 213.06 (-0.78%)
3 Healthcare Stocks That Concern Us

3 Healthcare Stocks That Concern Us

MYGN : 3.89 (-3.47%)
RGEN : 123.24 (-3.61%)
IQV : 148.99 (-2.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the...

See More

Key Turning Points

3rd Resistance Point 136.14
2nd Resistance Point 133.51
1st Resistance Point 128.37
Last Price 123.24
1st Support Level 120.60
2nd Support Level 117.97
3rd Support Level 112.83

See More

52-Week High 182.52
Fibonacci 61.8% 152.13
Fibonacci 50% 142.74
Fibonacci 38.2% 133.35
Last Price 123.24
52-Week Low 102.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar